Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126215071 | 12621507 | 1 | I | 201511 | 20151120 | 20160804 | 20160804 | EXP | CA-PFIZER INC-2015406326 | PFIZER | 51.00 | YR | F | Y | 0.00000 | 20160804 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126215071 | 12621507 | 1 | PS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 5 MG, 2X/DAY | Y | 203214 | 5 | MG | TABLET | BID | |||||
| 126215071 | 12621507 | 2 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 5 MG, 2X/DAY | Y | 203214 | 5 | MG | TABLET | BID | |||||
| 126215071 | 12621507 | 3 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 5 MG, 2X/DAY | Y | 203214 | 5 | MG | TABLET | BID | |||||
| 126215071 | 12621507 | 4 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 5 MG, 2X/DAY | Y | 203214 | 5 | MG | TABLET | BID | |||||
| 126215071 | 12621507 | 5 | SS | CELEBREX | CELECOXIB | 1 | UNK | 20998 | CAPSULE, HARD | ||||||||||
| 126215071 | 12621507 | 6 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Subcutaneous | 20 MG, WEEKLY | 11719 | 20 | MG | /wk | |||||||
| 126215071 | 12621507 | 7 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 10 MG, WEEKLY | 11719 | 10 | MG | /wk | |||||||
| 126215071 | 12621507 | 8 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 15 MG, WEEKLY | 11719 | 15 | MG | /wk | |||||||
| 126215071 | 12621507 | 9 | SS | PREDNISONE. | PREDNISONE | 1 | UNK | Y | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126215071 | 12621507 | 1 | Rheumatoid arthritis |
| 126215071 | 12621507 | 5 | Rheumatoid arthritis |
| 126215071 | 12621507 | 6 | Rheumatoid arthritis |
| 126215071 | 12621507 | 9 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126215071 | 12621507 | OT |
| 126215071 | 12621507 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126215071 | 12621507 | Condition aggravated | |
| 126215071 | 12621507 | Erythema of eyelid | |
| 126215071 | 12621507 | Eye pruritus | |
| 126215071 | 12621507 | Food poisoning | |
| 126215071 | 12621507 | Gastroenteritis | |
| 126215071 | 12621507 | Headache | |
| 126215071 | 12621507 | Hepatic enzyme increased | |
| 126215071 | 12621507 | Influenza | |
| 126215071 | 12621507 | Lung disorder | |
| 126215071 | 12621507 | Lung infection | |
| 126215071 | 12621507 | Nasopharyngitis | |
| 126215071 | 12621507 | Ocular hyperaemia | |
| 126215071 | 12621507 | Pain | |
| 126215071 | 12621507 | Rheumatoid arthritis | |
| 126215071 | 12621507 | Sinusitis | |
| 126215071 | 12621507 | Swelling | |
| 126215071 | 12621507 | Upper respiratory tract infection | |
| 126215071 | 12621507 | Urinary tract infection | |
| 126215071 | 12621507 | Vision blurred | |
| 126215071 | 12621507 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126215071 | 12621507 | 1 | 20151030 | 201511 | 0 | |
| 126215071 | 12621507 | 2 | 20151125 | 201601 | 0 | |
| 126215071 | 12621507 | 3 | 20160215 | 20160229 | 0 | |
| 126215071 | 12621507 | 4 | 20160323 | 20160628 | 0 | |
| 126215071 | 12621507 | 6 | 201509 | 0 |